Biotech: Page 2


  • Market growth
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Biogen’s Reata acquisition reflects biopharma’s inevitable M&A, IPO return to growth

    July’s announcement from the beleaguered drugmaker signals the kind of shift the industry could see more of as M&A and IPOs tick up once again.

    By Aug. 10, 2023
  • Sharon Rogers WoW header
    Image attribution tooltip
    Permission granted by AmyriaAD
    Image attribution tooltip
    Podcast

    Woman of the Week: AmyriAD Therapeutics’ Sharon Rogers

    The CEO of the Alzheimer’s-focused biotech discusses its phase 3-ready candidate and what it could contribute to the bustling field.

    By Taren Grom and Meagan Parrish • Aug. 9, 2023
  • test tube gene Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Cell and gene therapies

    How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

    By PharmaVoice staff
  • bleeding heart
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma’s rocky love affair with oxytocin

    Although research on using oxytocin as a drug has varied, Tonix Pharmaceuticals is banking on the “love hormone” to treat migraines, anxiety and more.

    By Kelly Bilodeau • Aug. 7, 2023
  • Michael Severino, CEO, Tessera Therapeutics
    Image attribution tooltip
    Permission granted by Tessera
    Image attribution tooltip
    Q&A // Biotech Spotlight

    Why AbbVie’s former president has high hopes for this Flagship-backed biotech

    The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

    By Aug. 7, 2023
  • Abstract genes with blue background
    Image attribution tooltip
    Permission granted by Bio-Rad
    Image attribution tooltip
    Sponsored by Bio-Rad

    A pioneering approach to biotherapeutic antibody discovery

    Immunotherapy has revolutionized cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous.

    By Kimberley Bryon-Dodd, PhD • Aug. 7, 2023
  • Iceberg
    Image attribution tooltip
    Joe Raedle / Staff via Getty Images
    Image attribution tooltip

    New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine

    A smaller player in the Alzheimer’s space, Prothena is approaching the next phase of treatments, including prevention and clinical trial evolution.

    By Aug. 3, 2023
  • Pfizer covid vaccine
    Image attribution tooltip
    Leon Neal via Getty Images
    Image attribution tooltip

    Is the COVID-19 market crashing?

    Pfizer’s recent earnings report could foretell major trouble in the market for pandemic products.

    By Aug. 3, 2023
  • Liver model
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    How CymaBay overcame a NASH failure for another shot at liver disease success

    The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.

    By Aug. 2, 2023
  • An AbbVie sign is seen on a building at the pharmaceutical company's U.S. headquarters.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    Biosimilar makers split strategies in bid to take on top-selling Humira

    In challenging AbbVie for share of a $19 billion drug market, competitors are testing whether high upfront discounts or behind-the-scenes rebates can win them an advantage.

    By Jonathan Gardner • July 26, 2023
  • A glass building with a sign that reads,  "Biogen."
    Image attribution tooltip

    Paul Marotta/Sipa USA/Newscom

    Image attribution tooltip

    Biogen’s layoffs are the latest in an industrywide slip

    Over 100 biotech companies so far this year have cut staff due to persistent funding challenges.

    By July 26, 2023
  • loic vinent head shot
    Image attribution tooltip
    Permission granted by Affini-T Therapeutics
    Image attribution tooltip
    Q&A

    In fast-growing KRAS field, this oncology veteran is chasing the toughest cancer targets

    Loïc Vincent, chief scientific officer at Affini-T, explains the company’s T cell approach and latest moves toward the clinic.

    By Alexandra Pecci • July 25, 2023
  • Genetic search
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A

    Google for genes? This AI company aims to curate the entire human genome.

    Genomenon’s acquisition of their contract scientific partner Boston Genetics will help them unlock the potential of genetic knowledge. 

    By July 20, 2023
  • Peter Benton
    Image attribution tooltip
    Permission granted by Worldwide Clinical Trials
    Image attribution tooltip
    Q&A

    A leading CRO’s chief exec on why a ‘brave new world’ of clinical research is here

    Peter Benton, co-CEO of Worldwide Clinical Trials, explains how the rise of the mid-sized pharma company has changed drug R&D.  

    By Taren Grom and Meagan Parrish • July 20, 2023
  • Pharma vials
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A

    As biologics boom, here’s how manufacturers are keeping up

    Stevanato’s focus on biologic-related vials and delivery devices has put it in a unique position amid a quickly growing market.

    By July 19, 2023
  • Artificial Intelligence concept brain with CPU
    Image attribution tooltip
    MF3d via Getty Images
    Image attribution tooltip

    AI’s great expectations

    With AI expectations riding high, here’s a look at some areas where the technology could be most useful in drug development. 

    By July 19, 2023
  • Professional headshot of Colleen Acosta.
    Image attribution tooltip
    Permission granted by Freya Biosciences
    Image attribution tooltip
    Profile

    What the 2014 Ebola outbreak taught this biotech CEO about persuasion

    A former WHO epidemiologist is applying lessons learned during the Ebola epidemic to her work leading a company at the forefront of women’s health: the reproductive microbiome.

    By Alexandra Pecci • July 18, 2023
  • Smart watch cardiac monitor
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    DCTs create fresh privacy challenges for review boards. Now there are guidelines.

    A new toolkit developed by industry stakeholders paves the way for faster reviews.

    By Kelly Bilodeau • July 17, 2023
  • fractural colors with white outline of mind
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    FDA’s upcoming psychedelic review looms large for a budding industry

    A new psychedelic guidance from the agency gives a clue into how it could analyze drugs in the space, but industry leaders are eager for more.

    By July 12, 2023
  • Merck's former global headquarters in Kenilworth, New Jersey
    Image attribution tooltip
    Permission granted by Onyx Equities
    Image attribution tooltip
    Q&A

    Merck’s New Jersey campus is getting a biotech makeover

    With a purchase of the pharma giant’s Kenilworth campus, Onyx Equities is looking to make the spot a go-to biotech hub.

    By July 11, 2023
  • bullseye
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // First 90 Days

    A rare disease veteran, Inozyme’s new CEO sharpens the company’s focus

    After taking the reins from the company’s founding CEO, Douglas Treco is guiding Inozyme through the clinic.

    By Alexandra Pecci • July 11, 2023
  • drug development
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Cancer R&D is shifting — here’s what’s changing most

    A report from IQVIA shows China gaining ground in cancer drug R&D, and a growing industry focus on new drug targets.

    By Kelly Bilodeau • July 10, 2023
  • A vial of Eisai and Biogen's Alzheimer's disease drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip

    Following FDA’s full approval of Leqembi, here’s what else is in the Alzheimer’s pipeline

    Leqembi’s U.S. approval is a milestone in Alzheimer’s research and medicine — and there are a few other late-stage biologic drugs that could follow.

    By July 7, 2023
  • Legal finance
    Image attribution tooltip
    matt_benoit via Getty Images
    Image attribution tooltip

    Pharma’s strike-from-all-sides attack on the IRA could be decided by the Supreme Court

    New lawsuits challenging the Inflation Reduction Act’s price negotiation program hit the government with multiple Constitution-based challenges.

    By Alexandra Pecci • July 6, 2023
  • Woman hands holding decorative model uterus on pink background. Top view
    Image attribution tooltip
    Elena Nechaeva via Getty Images
    Image attribution tooltip

    Women’s healthcare investments are hot. So where are the new menopause drugs?

    NK3 receptor antagonists offer a new option, but experts say more are needed.

    By Kelly Bilodeau • July 5, 2023
  • Colorful drug capsules against a yellow background
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The stories you’ve read the most in 2023 (so far)

    From staff shortages to presidential candidates and the M&A outlook, here are our most-read stories from the first half of the year.

    By PharmaVoice Staff • July 3, 2023